Cited by 3,634PARP inhibition in cancer therapyBRCA gene mutations in cancerAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Open access

Fong, Peter C., Boss, David S., Yap, Timothy A., Tutt, Andrew, Wu, Peijun, Mergui-Roelvink, Marja, Mortimer, Peter, Swaisland, Helen, Lau, Alan, O'Connor, Mark J., Ashworth, Alan, Carmichael, James, Kaye, Stan B., Schellens, Jan H.M., de Bono, Johann S.·2009·New England Journal of Medicine

DOI 10.1056/nejmoa0900212

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 mutation. We conducted a clinical evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor. METHODS: This was a phase 1 trial that included the analysis of pharmacokinetic and pharmacodynamic characteristics of olaparib. Selection was aimed at having a study population enriched in carriers of a BRCA1 or BRCA2 mutation. RESULTS: We enrolled and treated 60 patients; 22 were carriers of a BRCA1 or BRCA2 mutation and 1 had a strong family history of BRCA-associated cancer but declined to undergo mutational testing. The olaparib dose and schedule were increased from 10 mg daily for 2 of every 3 weeks to 600 mg twice daily continuously. Reversible dose-limiting toxicity was seen in one of eight patients receiving 400 mg twice daily (grade 3 mood alteration and fatigue) and two of five patients receiving 600 mg twice daily (grade 4 thrombocytopenia and grade 3 somnolence). This led us to enroll another cohort, consisting only of carriers of a BRCA1 or BRCA2 mutation, to receive olaparib at a dose of 200 mg twice daily. Other adverse effects included mild gastrointestinal symptoms. There was no obvious increase in adverse effects seen in the mutation carriers. Pharmacokinetic data indicated rapid absorption and elimination; pharmacodynamic studies confirmed PARP inhibition in surrogate samples (of peripheral-blood mononuclear cells and plucked eyebrow-hair follicles) and tumor tissue. Objective antitumor activity was reported only in mutation carriers, all of whom had ovarian, breast, or prostate cancer and had received multiple treatment regimens. CONCLUSIONS: Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation. (ClinicalTrials.gov number, NCT00516373.)

Integrity signals

Registry

Crossref · 10.1056/nejmoa0900212

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Self-citation
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N. C., Tutt, A. N. J., & Ashworth, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1457 · Cited by 1,690
Self-citation
The PARP superfamily
Amé, J., Spenlehauer, C., & de MURCIA, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,463
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1691 · Cited by 1,405
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O’Connor, M. J., Tutt, A. N. J., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,311
Self-citation
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086

Flagged first, then by citations

Show all 30 references

Research works printed but not linked: 1

10.1042/BST0290655 · DOI

Sorted by citations

Items 401–500 of 1,012

Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer
Maxwell, K. N., Wubbenhorst, B. S., D'Andrea, K. P., Garman, B., Long, J. M., Powers, J. M., Rathbun, K., Stopfer, J. E., Zhu, J., Bradbury, A. R., et al. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.176 · Cited by 158
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial
Hanna, C. R., Kurian, K. M., Williams, K., Watts, C., Jackson, A., Carruthers, R., Strathdee, K. E., Cruickshank, G. S., Dunn, L., Erridge, S., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa104 · Cited by 163
Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors
Neri, P. E., Ren, L., Gratton, K., Stebner, E., Johnson, J., Klimowicz, A. C., Duggan, P. R., Tassone, P., Mansoor, A., Stewart, D. A., et al. (2011) · Blood · doi:10.1182/blood-2011-06-363911 · Cited by 159
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence
Wang, Q., Peng, H., Qi, X., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0199-6 · Cited by 162
Targeted Therapy for Breast Cancer Prevention
den Hollander, P., Savage, M. I., & Brown, P. H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00250 · Cited by 161
Biomarkers in triple negative breast cancer: A review
Yadav, B. S. (2015) · World Journal of Clinical Oncology · doi:10.5306/wjco.v6.i6.252 · Cited by 166
AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells
Min, A., Im, S., Jang, H., Kim, S., Lee, M., Kim, D. K., Yang, Y., Kim, H. J., Lee, K.-H., Kim, J. W., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0378 · Cited by 160
Self-citation
Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer
Anders, C. K., Winer, E. P., Ford, J. M., Dent, R. A., Silver, D. P., Sledge, G. W., & Carey, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0939 · Cited by 159
The genomic and transcriptional landscape of primary central nervous system lymphoma
Radke, J., Ishaque, N., Koll, R., Gu, Z., Schumann, E., Sieverling, L., Uhrig, S., Hübschmann, D., Toprak, U. H., López, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30050-y · Cited by 158
Hereditary ovarian cancer: Beyond the usual suspects
Pennington, K. P., & Swisher, E. M. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.12.415 · Cited by 159
Clinical Validation of KRAS, BRAF, and EGFR Mutation Detection Using Next-Generation Sequencing
Lin, M., Mosier, S. L., Thiess, M., Beierl, K. F., Debeljak, M., Tseng, L., Chen, G., Yegnasubramanian, S., Ho, H., Cope, L., et al. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcpmwgwgo34egod · Cited by 152
DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker
Heyn, H., Carmona, F. J., Gómez, A., Ferreira, H. J., Bell, J. T., Sayols, S., Ward, K. J., Stefánsson, Ó. A., Morán, S., Sandoval, J., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs321 · Cited by 152
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers
Keung, M., Wu, Y., & Vadgama, J. V. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040435 · Cited by 158
Genomic instability in breast cancer: Pathogenesis and clinical implications
Kwei, K. A., Kung, Y., Salari, K., Holcomb, I. N., & Pollack, J. R. (2010) · Molecular Oncology · doi:10.1016/j.molonc.2010.04.001 · Cited by 157
Effect of ASCO/CAP guidelines for determining ER status on molecular subtype
Deyarmin, B., Kane, J. L., Valente, A. L., van Laar, R., Gallagher, C., Shriver, C. D., & Ellsworth, R. E. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2588-8 · Cited by 149
Clinical and molecular complexity of breast cancer metastases
Kimbung, S., Loman, N., & Hedenfalk, I. A. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.009 · Cited by 154
Advances in using PARP inhibitors to treat cancer
Kummar, S., Chen, A. P., Parchment, R. E., Kinders, R. J., Ji, J., Tomaszewski, J. E., & Doroshow, J. H. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-25 · Cited by 151
Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
Mukhopadhyay, A., Plummer, E. R., Elattar, A., Soohoo, S., Uzir, B. F., Quinn, J. E., McCluggage, W. G., Maxwell, P., Aneke, H., Curtin, N. J., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0324 · Cited by 151
Ten-Year Survival in Patients With BRCA1-Negative and BRCA1-Positive Breast Cancer
Huzarski, T., Byrski, T., Gronwald, J., Górski, B., Domagała, P., Cybulski, C., Oszurek, O., Szwiec, M., Gugała, K., Stawicka, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.3571 · Cited by 149
Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy
Wen, S., Wang, G., Zhang, Y., Bu, F., Zhang, S., Miller, D. D., Li, W., Ouyang, L., & Wang, Y. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00100 · Cited by 155
Familial Pancreatic Cancer
Brune, K. A., & Klein, A. P. (2008) · Springer eBooks · doi:10.1007/978-0-387-69252-4_5 · Cited by 149
MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers
Vilar, E., Bartnik, C. M., Stenzel, S. L., Raskin, L., Ahn, J., Moreno, V. R., Mukherjee, B., Iniesta, M. D., Morgan, M. A., Rennert, G., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1120 · Cited by 148
Mass spectrometry for the assessment of the occurrence and biological consequences of DNA adducts
Liu, S., & Wang, Y. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00316d · Cited by 150
Update on triple-negative breast cancer: prognosis and management strategies
Neven, P., Brouckaert, Wildiers, & Floris, G. (2012) · International Journal of Women s Health · doi:10.2147/ijwh.s18541 · Cited by 147
Ubiquitylation, neddylation and the DNA damage response
Brown, J. S., & Jackson, S. P. (2015) · Open Biology · doi:10.1098/rsob.150018 · Cited by 155
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition
Au‐Yeung, G., Lang, F., Azar, W. J., Mitchell, T. J., Jarman, K. E., Lackovic, K., Aziz, D., Cullinane, C. M., Pearson, R. B., Mileshkin, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0620 · Cited by 147
PARP inhibitors: the race is on
Brown, J. S., Kaye, S. B., & Yap, T. A. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.67 · Cited by 149
Self-citation
Biallelic Deleterious BRCA1 Mutations in a Woman with Early-Onset Ovarian Cancer
Domchek, S. M., Tang, J.-B., Stopfer, J. E., Lilli, D. R., Hamel, N., Tischkowitz, M. D., Monteiro, Á. N. A., Messick, T. E., Powers, J., Yonker, A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0421 · Cited by 152
Genomic profiling of breast tumours in relation to BRCAabnormalities and phenotypes
Stefánsson, Ó. A., Jonasson, J. G., Jóhannsson, Ó. Þ., Ólafsdóttir, K., Steinarsdóttir, M., Valgeirsdóttir, S., & Eyfjord, J. E. (2009) · Breast Cancer Research · doi:10.1186/bcr2334 · Cited by 151
Targeted Therapies for Ovarian Cancer
Grunewald, T., & Ledermann, J. A. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.12.001 · Cited by 150
Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life
Morganti, S., Tarantino, P., Ferraro, E., D’Amico, P., Viale, G., Trapani, D., Duso, B. A., & Curigliano, G. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.11.008 · Cited by 151
The Changing Role of Pathology in Breast Cancer Diagnosis and Treatment
Leong, A. S. ‐., & Zhuang, Z. (2011) · Pathobiology · doi:10.1159/000292644 · Cited by 144
Inherited predisposition to breast cancer among African American women
Churpek, J. E., Walsh, T., Zheng, Y., Moton, Z., Thornton, A., Lee, M. K., Casadei, S., Watts, A. C., Neistadt, B., Churpek, M. M., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3195-0 · Cited by 144
The changing therapeutic landscape of castration-resistant prostate cancer
Yap, T. A., Zivi, A., Omlin, A. G., & Bono, J. S. D. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.117 · Cited by 147
Self-citation
PARP inhibitors in ovarian cancer: Current status and future promise
Liu, J. F., Konstantinopoulos, P. A., & Matulonis, U. A. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.039 · Cited by 147
Optimal first-line treatment in ovarian cancer
Raja, F. A., Chopra, N., & Ledermann, J. A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds315 · Cited by 144
RAD-ical New Insights into RAD51 Regulation
Sullivan, M. R., & Bernstein, K. A. (2018) · Genes · doi:10.3390/genes9120629 · Cited by 152
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
Brighty, G. J., Botham, R. C., Li, S., Nelson, L. T., Mortenson, D. E., Li, G., Morisseau, C. H. P., Wang, H., Hammock, B. D., Sharpless, K. B., et al. (2020) · Nature Chemistry · doi:10.1038/s41557-020-0530-4 · Cited by 148
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
Min, A., Im, S., Yoon, Y., Song, S., Nam, H.-J., Hur, H.-S., Kim, H., Lee, K.-H., Han, S., Oh, D., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0950 · Cited by 146
Self-citation
Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
Nonnekens, J., van Kranenburg, M., Beerens, C. E. M. T., Suker, M., Doukas, M., van Eijck, C. H. J., de Jong, M., & van Gent, D. C. (2016) · Theranostics · doi:10.7150/thno.15311 · Cited by 149
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer
Choi, Y. E., Meghani, K. A., Brault, M. E., Leclerc, L., He, Y. J., Day, T. A., Elias, K. M., Drapkin, R., Weinstock, D. M., Dao, F., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.046 · Cited by 142
Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
Bonadio, R. R. D. C. C., Fogace, R. N., Miranda, V. D. C., & Estevez-Diz, M. D. P. (2018) · Clinics · doi:10.6061/clinics/2018/e450s · Cited by 142
Drug discovery in advanced prostate cancer: translating biology into therapy
Yap, T. A., Smith, A. D., Ferraldeschi, R., Al‐Lazikani, B., Workman, P., & Bono, J. S. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.120 · Cited by 143
Self-citation
Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update
Jain, P. G., & Patel, B. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.024 · Cited by 142
Evolutionary history of the poly(ADP-ribose) polymerase gene family in eukaryotes
Citarelli, M., Teotia, S., & Lamb, R. S. (2010) · BMC Evolutionary Biology · doi:10.1186/1471-2148-10-308 · Cited by 147
Therapeutic targets in triple negative breast cancer
O'Toole, S. A., Beith, J. M., Millar, E. K. A., West, R. H., McLean, A. E. B., Cazet, A., Swarbrick, A., & Oakes, S. R. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201361 · Cited by 140
The Use of Gamma-H2AX as a Biodosimeter for Total-Body Radiation Exposure in Non-Human Primates
Redon, C. E., Nakamura, A., Gouliaeva, K., Rahman, A., Blakely, W. F., & Bonner, W. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015544 · Cited by 142
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1
Drost, R., Dhillon, K. K., van der Gulden, H. M. L., van der Heijden, I., Brandsma, I., Cruz, C., Chondronasiou, D., Castroviejo‐Bermejo, M., Boon, U., Schut, E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci70196 · Cited by 142
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
Besse, B., Tostivint, E. P., Park, K., Hartl, S., Forde, P. M., Hochmair, M. J., Awad, M. M., Thomas, M., Goss, G. D., Wheatley‐Price, P., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02808-y · Cited by 144
Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
Ang, J. E., Gourley, C., Powell, C. B., High, H. A., Shapira‐Frommer, R., Castonguay, V., Grève, J. D., Atkinson, T., Yap, T. A., Sandhu, S. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1262 · Cited by 140
Self-citation
A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy
Srivas, R., Shen, J. P., Yang, C. C., Sun, S. M., Li, J., Gross, A. M., Jensen, J., Licon, K., Bojorquez-Gomez, A., Klepper, K., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.06.022 · Cited by 143
Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway
Massihnia, D., Galvano, A., Fanale, D., Perez, A., Castiglia, M., Incorvaia, L., Listì, A., Rizzo, S., Cicero, G., Bazan, V., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10858 · Cited by 143
Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA‐repair gene mutations in prostate cancer
Velho, P. I., Silberstein, J. L., Markowski, M. C., Luo, J., Lotan, T. L., Isaacs, W. B., & Antonarakis, E. S. (2018) · The Prostate · doi:10.1002/pros.23484 · Cited by 139
Triple-negative breast cancer: new perspectives for targeted therapies
Tomao, F., Tomao, F., Rossi, L., Zaccarelli, E., Caruso, D., Minozzi, M., Frati, L., Papa, A., & Vici (2015) · OncoTargets and Therapy · doi:10.2147/ott.s67673 · Cited by 140
Antitumor Activity in RAS -Driven Tumors by Blocking AKT and MEK
Tolcher, A. W., Khan, K. H., Ong, M., Banerji, U., Papadimitrakopoulou, V. A., Gandara, D. R., Patnaik, A., Baird, R. D., Olmos, D., Garrett, C. R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1901 · Cited by 140
Self-citation
BRCA mutation in ovarian cancer: testing, implications and treatment considerations
Neff, R. T., Senter, L. A., & Salani, R. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017714993 · Cited by 142
Breast cancer: The translation of big genomic data to cancer precision medicine
Low, S., Zembutsu, H., & Nakamura, Y. (2017) · Cancer Science · doi:10.1111/cas.13463 · Cited by 142
Leveraging the replication stress response to optimize cancer therapy
Cybulla, E., & Vindigni, A. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00518-6 · Cited by 144
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
Ding, X., Chaudhuri, A. R., Callén, E., Pang, Y., Biswas, K., Klarmann, K. D., Martin, B. K., Burkett, S. S., Cleveland, L., Stauffer, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12425 · Cited by 140
Platinum resistance in breast and ovarian cancer cell lines
Eckstein, N. (2011) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-30-91 · Cited by 138
Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity
Lauschke, V. M., Zhou, Y., & Ingelman‐Sundberg, M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.01.002 · Cited by 135
Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy
Park, Y., Chui, M. H., Rahmanto, Y. S., Yu, Z.-C., Shamanna, R. A., Bellani, M. A., Gaillard, S. L., Ayhan, A., Viswanathan, A., Seidman, M. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4222 · Cited by 138
Targeting DNA repair pathway in cancer: Mechanisms and clinical application
Wang, M., Chen, S., & Ao, D. (2021) · MedComm · doi:10.1002/mco2.103 · Cited by 140
Secondary mutations of BRCA1/2 and drug resistance
Dhillon, K. K., Swisher, E. M., & Taniguchi, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01840.x · Cited by 135
PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy
Domagała, P., Huzarski, T., Lubiński, J., Gugała, K., & Domagała, W. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1441-2 · Cited by 137
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions
Basourakos, S. P., Li, L., Aparicio, A. M., Corn, P. G., Kim, J., & Thompson, T. C. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666161214114948 · Cited by 136
Synthetic Lethality Exploitation by an Anti–Trop-2-SN-38 Antibody–Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2 –wild-type Triple-Negative Breast Cancer
Cardillo, T. M., Sharkey, R. M., Rossi, D. L., Arrojo, R., Mostafa, A. A., & Goldenberg, D. M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2401 · Cited by 133
Advances in the use of PARP inhibitor therapy for breast cancer
McCann, K. E., & Hurvitz, S. A. (2018) · Drugs in Context · doi:10.7573/dic.212540 · Cited by 136
The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment
Li, S., Wang, L., Wang, Y., Zhang, C., Hong, Z., & Han, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01360-x · Cited by 141
Collateral lethality: a new therapeutic strategy in oncology
Muller, F. L., Aquilanti, E. A., & DePinho, R. A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.002 · Cited by 132
Poly(ADP-Ribose) Polymerase Inhibition as a Model for Synthetic Lethality in Developing Radiation Oncology Targets
Chalmers, A. J., Lakshman, M., Chan, N. H. L., & Bristow, R. G. (2010) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2010.06.001 · Cited by 136
PARP-1 Regulates Metastatic Melanoma through Modulation of Vimentin-induced Malignant Transformation
Rodríguez, M. I., Peralta-Leal, A., O’Valle, F., Rodríguez-Vargas, J. M., González-Flores, A., Majuelos‐Melguizo, J., López, L., Serrano, S., de Herreros, A. G., Rodríguez-Manzaneque, J. C., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003531 · Cited by 140
PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy
Fraser, M. E., Zhao, H. W., Luoto, K. R., Lundin, C., Coackley, C. L., Chan, N. H. L., Joshua, A. M., Bismar, T. A., Evans, A. J., Helleday, T., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2189 · Cited by 138
Mutational Signatures in Breast Cancer: The Problem at the DNA Level
Nik‐Zainal, S., & Morganella, S. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2810 · Cited by 139
Advances in anti-breast cancer drugs and the application of nano-drug delivery systems in breast cancer therapy
Fang, X., Cao, J., & Shen, A. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101662 · Cited by 135
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
Lheureux, S., Oaknin, A., Garg, S., Bruce, J. P., Madariaga, A., Dhani, N. C., Bowering, V. L., White, J., Accardi, S., Tan, D. S. P., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4121 · Cited by 134
Causes and consequences of DNA single-strand breaks
Caldecott, K. W. (2023) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2023.11.001 · Cited by 141
Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function
Feng, F. Y.-C., Bono, J. S. D., Rubin, M. A., & Knudsen, K. E. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.016 · Cited by 133
A survey of yeast genomic assays for drug and target discovery
Smith, A. M., Ammar, R., Nislow, C., & Giaever, G. N. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.04.012 · Cited by 137
Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited
Lupo, B., & Trusolino, L. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.004 · Cited by 135
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA -Mutant Ovarian Cancer
Kummar, S., Oza, A. M., Fleming, G. F., Sullivan, D. M., Gandara, D. R., Naughton, M. J., Villalona-Calero, M. A., Morgan, R. J., Szabó, P., Youn, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2565 · Cited by 131
Current status of poly(ADP-ribose) polymerase inhibitors and future directions
Ohmoto, A., & Yachida, S. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s139336 · Cited by 131
Radium-223 mechanism of action: implications for use in treatment combinations
Morris, M. J., Corey, E., Guise, T. A., Gulley, J. L., Kelly, W. K., Quinn, D. I., Scholz, A., & Sgouros, G. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0251-x · Cited by 133
Progress towards a clinically-successful ATR inhibitor for cancer therapy
Barnieh, F. M., Loadman, P. M., & Falconer, R. A. (2021) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2021.100017 · Cited by 134
Donafenib and GSK‐J4 Synergistically Induce Ferroptosis in Liver Cancer by Upregulating HMOX1 Expression
Zheng, C., Zhang, B., Li, Y., Liu, K., Wei, W., Liang, S., Guo, H., Ma, K., Liu, Y., Wang, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202206798 · Cited by 137
DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target
Jalal, S. I., Earley, J. N., & Turchi, J. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0761 · Cited by 138
Integrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129
PARP inhibitors in ovarian cancer
Ledermann, J. A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw094 · Cited by 132
Precision medicine: the foundation of future cancer therapeutics
Shin, S. H., Bode, A. M., & Dong, Z. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0016-z · Cited by 132
Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology
Bruin, M. A. C., Sonke, G. S., Beijnen, J. H., & Huitema, A. D. R. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01167-6 · Cited by 129
BRCA1epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer
Stefánsson, Ó. A., Villanueva, A., Vidal, A., Martí, L., & Esteller, M. (2012) · Epigenetics · doi:10.4161/epi.22561 · Cited by 130
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
Williamson, C. T., Kubota, E., Hamill, J. D., Klimowicz, A. C., Ye, R., Muzik, H., Dean, M. L., Tu, L., Gilley, D. P., Magliocco, A. M., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200229 · Cited by 131
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib
Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E. J., Middleton, M. R., Friedlander, M. L., Gourley, C., Plummer, R., Rustin, G. J. S., et al. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0435-8 · Cited by 129
Self-citation
PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling
van Beek, L., McClay, É., Patel, S., Schimpl, M., Spagnolo, L., & de Oliveira, T. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105112 · Cited by 136
Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping
Oxnard, G. R., Miller, V. A., Robson, M. E., Azzoli, C. G., Pao, W. J., Ladanyi, M., & Arcila, M. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318250ed9d · Cited by 130
Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy
Peddi, P. F., Ellis, M. J., & Ma, C. X. (2011) · International Journal of Breast Cancer · doi:10.1155/2012/217185 · Cited by 134
Targeting homologous recombination, new pre-clinical and clinical therapeutic combinations inhibiting RAD51
Ward, A., Khanna, K. K., & Wiegmans, A. P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.006 · Cited by 129
Sensitization to Radiation and Alkylating Agents by Inhibitors of Poly(ADP-ribose) Polymerase Is Enhanced in Cells Deficient in DNA Double-Strand Break Repair
Löser, D. A., Shibata, A., Shibata, A., Woodbine, L. J., Jeggo, P. A., & Chalmers, A. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1027 · Cited by 129
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
Cerrato, A., Morra, F., & Celetti, A. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0456-2 · Cited by 132
PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
Geenen, J. J. J., Linn, S. C., Beijnen, J. H., & Schellens, J. H. M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0587-4 · Cited by 127
Self-citation

Authors: Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., Ashworth, A., Carmichael, J., Kaye, S. B., Schellens, J. H. M., & de Bono, J. S.
Affiliations: National Health Service (GB)
The Netherlands Cancer Institute (NL)
Institute of Cancer Research (GB)
AstraZeneca (United Kingdom) (GB)
Utrecht University (NL)
ORCID: Fong, Peter C.
Yap, Timothy A.
Tutt, Andrew
Wu, Peijun
Mortimer, Peter
Lau, Alan
Ashworth, Alan
Kaye, Stan B.
Schellens, Jan H.M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2009-07-09
Volume: 361
Issue: 2
Pages: 123-134
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa0900212
OpenAlex: W2171972386
Cited by: 3,634
References: 30
Citations by year: 2026: 79 · 2025: 113 · 2024: 126 · 2023: 152 · 2022: 188 · 2021: 189 · 2020: 173 · 2019: 195 · 2018: 190 · 2017: 214 · 2016: 249 · 2015: 252 · 2014: 244 · 2013: 247 · 2012: 285
FWCI: 170.91
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Research Portal (King's College London) (submittedVersion)
Funders: AstraZeneca
Royal Marsden NHS Foundation Trust
NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
Cancer Research UK (A8363)
National Institute for Health and Care Research
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: olaparib, PARP inhibitors, BRCA1 mutation carriers, BRCA2 mutation carriers, synthetic lethality, DNA repair deficiency, ovarian cancer, breast cancer, prostate cancer, pharmacokinetics, pharmacodynamics, dose-limiting toxicity, thrombocytopenia, anticancer activity
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Female, Heterozygote, Humans, Male, Middle Aged, Neoplasms, Phthalazines, Piperazines, Drug Design, Germ-Line Mutation, Genes, BRCA1, Genes, BRCA2, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks